Milrinone Zentiva

Milrinone, the active ingredient in Milrinone Zentiva, is a phosphodiesterase 3 inhibitor presented as an injectable solution for intravenous use. It is employed to improve cardiac output in patients with acute decompensated heart failure or cardiogenic shock.

GNH USA supplies Milrinone Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Milrinone is an inotropic agent used in the management of severe cardiac conditions where low cardiac output is a concern. - Acute decompensated heart failure: enhances myocardial contractility to improve systemic perfusion. - Cardiogenic shock: provides rapid hemodynamic support to sustain blood pressure and organ perfusion. - Low cardiac output state (post‑operative or after myocardial infarction): helps maintain adequate circulation while other therapies are optimized.

Milrinone may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Hypotension: reduction in systemic blood pressure. - Tachyarrhythmias: increased heart rate or irregular rhythm. - Headache: mild to moderate discomfort. - Nausea: gastrointestinal upset. - Flushing: warmth and redness of the skin. - Diarrhea: loose stools.

Serious or Rare Side Effects: - Severe hypotension: potentially leading to shock. - Ventricular arrhythmias: life‑threatening heart rhythm disturbances. - Myocardial ischemia: reduced blood flow to heart muscle. - Thrombocytopenia: low platelet count increasing bleeding risk. - Anaphylactic reactions: severe allergic response. - Cardiac arrest: sudden loss of heart function.

Milrinone requires careful monitoring and specific precautions to ensure patient safety. - Blood pressure monitoring: watch for hypotension and adjust infusion rate as needed. - Cardiac rhythm surveillance: continuous ECG to detect arrhythmias. - Renal function assessment: dose may need adjustment in renal impairment. - Recent myocardial infarction: use cautiously due to risk of ischemia. - Concomitant vasodilators: avoid excessive blood pressure drops. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Milrinone can interact with several drug classes, necessitating vigilance.

Major Interactions (Avoid): - Other phosphodiesterase‑3 inhibitors: additive inotropic and vasodilatory effects. - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase plasma concentrations. - Concurrent high‑dose vasodilators: risk of profound hypotension. - Multiple inotropes: heightened arrhythmia potential. - Class IA anti‑arrhythmics: increased pro‑arrhythmic risk.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may blunt desired inotropic response. - Diuretics: monitor electrolyte balance and volume status. - ACE inhibitors or ARBs: watch for additive blood pressure effects. - Calcium channel blockers: potential for altered vascular tone. - Anticoagulants: monitor for bleeding if thrombocytopenia occurs.